The State of Weight-Loss Drugs
1Digest
This podcast delves into the rapidly expanding market for GLP-1 weight-loss drugs, projected to reach $150 billion annually, questioning the validity of this figure. It examines the dominant players, Eli Lilly and Novo Nordisk, and their respective drugs, semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro). The podcast details the mechanism of action of GLP-1 agonists, mimicking natural hormones to regulate appetite and insulin, highlighting their longer half-life compared to natural GLP-1. Significant sales growth and high discontinuation rates are discussed, alongside side effects like gastrointestinal issues and mood changes, raising concerns about long-term adherence and prescription to children. The FDA's announcement ending the semaglutide shortage is analyzed, impacting compounding pharmacies like Hims & Hers and the legal landscape. Ethical concerns regarding the use of GLP-1 drugs in individuals with eating disorders are explored, acknowledging the lack of substantial data. Patent expirations for Ozempic (2032) and Mounjaro (2036) are discussed, impacting future competition and the potential for generic drugs. The development of non-peptide weight-loss pills, like Eli Lilly's Orforglipron, is examined, along with its advantages and disadvantages. Investment strategies are assessed, considering market valuations of Eli Lilly, Novo Nordisk, and online pharmacies, and the potential for these stocks to be undervalued or overvalued. Finally, the podcast explores the competitive landscape, including smaller companies like Viking Therapeutics and Structure Therapeutics, and the impact of upcoming clinical trials on the market's future, including economic impacts on food consumption and bariatric surgery.
Outlines
The GLP-1 Weight-Loss Drug Market: Growth, Mechanisms, and Challenges
This section introduces the rapidly growing market for GLP-1 weight-loss drugs, questioning the $150 billion projection. It covers the dominance of Eli Lilly and Novo Nordisk, the mechanisms of GLP-1 drugs, their effectiveness, side effects, and high discontinuation rates. Concerns about prescribing to children and the impact on individuals with eating disorders are also addressed.
FDA Regulations, Compounding Pharmacies, and Future Competition
This section discusses the FDA's announcement ending the semaglutide shortage and its impact on compounding pharmacies. It analyzes the legal aspects of compounded GLP-1 drugs, patent expirations for Ozempic and Mounjaro, and the competitive landscape with generic drugs and newer formulations.
Investment Strategies and Market Outlook
This section assesses the market valuation of key players, including investment strategies and considerations for retail investors. It explores the potential for these stocks to be undervalued or overvalued, considering market competition, drug effectiveness, and insurance coverage. The economic impacts and future outlook of the market are also discussed.
Keywords
GLP-1 Agonists
A class of drugs mimicking glucagon-like peptide-1, regulating appetite and insulin production for weight loss and diabetes treatment. Examples include semaglutide and tirzepatide.
Semaglutide
A GLP-1 receptor agonist in weight-loss medications like Ozempic and Wegovy, mimicking GLP-1 to increase satiety and improve insulin sensitivity.
Tirzepatide
A dual GLP-1 and GIP receptor agonist in Mounjaro, offering potentially greater weight loss due to its dual mechanism.
Obesity Epidemic
A significant public health crisis with high overweight and obesity rates, increasing risks of various health problems.
Compounding Pharmacy
Pharmacies preparing customized medications, including specific dosages or formulations not commercially available.
Patent Cliff
The period when a drug's patent expires, leading to generic competitors and declining sales.
Non-peptide Agonist
A drug mimicking a peptide hormone but not a peptide itself, offering advantages in oral delivery and manufacturing.
Ozempic
A brand name for semaglutide, a GLP-1 receptor agonist used for weight loss and diabetes management.
Mounjaro
A brand name for tirzepatide, a dual GLP-1 and GIP receptor agonist used for weight loss and diabetes management.
Weight Loss Drugs
Medications used to facilitate weight loss, including GLP-1 agonists and other emerging therapies.
Q&A
What are the main mechanisms of action of GLP-1 drugs, and how do they differ from natural GLP-1?
GLP-1 drugs mimic natural GLP-1, regulating appetite and insulin production. Their longer half-life allows for sustained effects with less frequent dosing.
What are the major side effects associated with GLP-1 drugs, and how significant are these concerns?
Common side effects include gastrointestinal issues, mood changes, and insomnia. Severity varies, and many users discontinue treatment due to side effects.
How does the FDA's announcement regarding the end of the semaglutide shortage impact compounding pharmacies and large pharmaceutical companies?
While the shortage ends for commercially produced semaglutide, compounding pharmacies maintain a market share. Large companies face patent cliffs.
What are some key upcoming clinical trials that investors should be watching, and what are their potential implications?
Key trials include Eli Lilly's retatrotide and Novo Nordisk's oral drug, potentially leading to more potent drugs or convenient oral formulations. Results will significantly impact market share and valuations.
How should retail investors approach investing in the weight-loss drug market?
A basket approach, diversifying investments across several companies, is recommended to mitigate risk.
Show Notes
$150 billion. That’s how much some experts estimate weight-loss drugs could bring in in sales within the next five years.
Motley Fool analyst Karl Thiel joins Ricky Mulvey to check in on the GLP-1 landscape. They also discuss:
- How weight-loss drugs actually work, and how big-name prescriptions differ from each other.
- What investors need to know about Ozempic and Mounjarno’s patent cliffs.
- The scenarios in which Novo Nordisk and Eli Lilly are actually undervalued.
Companies discussed: LLY, NOVO, HIMS, PFE, RHHBY, VKTX, GPCR, ISRG
Host: Ricky Mulvey
Guest: Karl Thiel
Producer: Mary Long
Engineer: Rick Engdahl
Learn more about your ad choices. Visit megaphone.fm/adchoices
Table of contents
United States
